StreetInsider.com News Articles

Form 8-K OPKO HEALTH, INC. For: Jun 18

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665981.html

Form 8-K OPKO HEALTH, INC. For: Jun 18

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665981.html

ENTERA BIO shares preclinical data for two pipeline drugs at ENDO 2026

Tue, 16 Jun 2026 08:33:28 -0400

Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.

EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in

ENTERA BIO shares preclinical data for two pipeline drugs at ENDO 2026

Tue, 16 Jun 2026 08:33:28 -0400

ENTERA BIO shares preclinical data for two pipeline drugs at ENDO 2026

Tue, 16 Jun 2026 08:33:28 -0400

ENTERA BIO shares preclinical data for two pipeline drugs at ENDO 2026

Tue, 16 Jun 2026 08:33:28 -0400

ENTERA BIO shares preclinical data for two pipeline drugs at ENDO 2026

Tue, 16 Jun 2026 08:33:28 -0400

OPKO Biologics presents preclinical data for acromegaly drug candidate

Mon, 15 Jun 2026 08:00:22 -0400

OPKO Health Inc. (NASDAQ: OPK) subsidiary OPKO Biologics presented preclinical data for its drug candidate OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting on June 15.

The preclinical study data showed that OPK8801001 produced dose-dependent suppression of insulin-like growth factor-1 (IGF-1), which serves as a marker for disease activity in acromegaly. The company reported that in vitro data demonstrated the drug candidate's growth hormone receptor antagonism was approximately 20-fold greater than Pegvisomant, an existing acromegaly therapy.

The findings suggest potential for weekly dosing compared to currently available daily treatments for the condition. Moran Golan, Director of Preclinical & Clinical Pharmacology at

OPKO Biologics presents preclinical data for acromegaly drug candidate

Mon, 15 Jun 2026 08:00:22 -0400

OPKO Health Inc. (NASDAQ: OPK) subsidiary OPKO Biologics presented preclinical data for its drug candidate OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting on June 15.

The findings suggest potential for weekly dosing compared to currently available daily treatments for the condition. Moran Golan, Director of Preclinical & Clinical Pharmacology at

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

Mon, 15 Jun 2026 08:00:00 -0400

MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society’s annual meeting. The poster, “Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly,” available here, was presented by Moran Golan, Ph.D., Director of Preclinical & Clinical Pharmacology at OPKO Biologics.

In vivo data showed that OPK8801001 produced robust, dose-dependent, sustained suppression of insulin-like growth factor-1 (IGF-1), a marker of disease activity in acromegaly. The findings

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

Mon, 15 Jun 2026 08:00:00 -0400

In vivo data showed that OPK8801001 produced robust, dose-dependent, sustained suppression of insulin-like growth factor-1 (IGF-1), a marker of disease activity in acromegaly. The findings

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

Mon, 15 Jun 2026 08:00:00 -0400

In vivo data showed that OPK8801001 produced robust, dose-dependent, sustained suppression of insulin-like growth factor-1 (IGF-1), a marker of disease activity in acromegaly. The findings

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

Mon, 15 Jun 2026 08:00:00 -0400

In vivo data showed that OPK8801001 produced robust, dose-dependent, sustained suppression of insulin-like growth factor-1 (IGF-1), a marker of disease activity in acromegaly. The findings

Form DEFA14A OPKO HEALTH, INC.

Fri, 15 May 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260515/26507044.html

Form DEFA14A OPKO HEALTH, INC.

Fri, 15 May 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260515/26507044.html

OPKO's ModeX to present CAR-T cell generation data at gene therapy meeting

Tue, 12 May 2026 08:00:52 -0400

ModeX Therapeutics, a subsidiary of OPKO Health (NASDAQ: OPK), will present preclinical data on its MDX3001 candidate at the American Society of Gene & Cell Therapy 2026 Annual Meeting in Boston from May 11-15.

The data demonstrates in vivo generation of CAR-T cells and B-cell depletion using the company's CD3xCD28 antibody-conjugated lipid nanoparticle/mRNA platform in animal models. Studies showed B-cell depletion in blood and lymphoid tissues including spleen, bone marrow, and lymph nodes in both humanized mouse and non-human primate models.

The platform combines CD3 with CD28 costimulatory engagement to enable T-cell transfection, activation, and functional CAR-T cell generation directly in vivo.

OPKO's ModeX to present CAR-T cell generation data at gene therapy meeting

Tue, 12 May 2026 08:00:52 -0400

The platform combines CD3 with CD28 costimulatory engagement to enable T-cell transfection, activation, and functional CAR-T cell generation directly in vivo.

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Tue, 12 May 2026 08:00:00 -0400

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models

Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models. The data, generated using ModeX’s CD3xCD28 antibody-conjugated lipid nanoparticle (LNP)/mRNA platform, will be presented at the ASGCT 2026 Annual

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Tue, 12 May 2026 08:00:00 -0400

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models

Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Tue, 12 May 2026 08:00:00 -0400

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models

Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Tue, 12 May 2026 08:00:00 -0400

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models

Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Form DEFA14A OPKO HEALTH, INC.

Thu, 30 Apr 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260430/26407533.html

Form DEFA14A OPKO HEALTH, INC.

Thu, 30 Apr 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260430/26407533.html

Form ARS OPKO HEALTH, INC. For: Dec 31

Thu, 30 Apr 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260430/26407611.html

Form ARS OPKO HEALTH, INC. For: Dec 31

Thu, 30 Apr 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260430/26407611.html